LAWRENCEVILLE, N.J., May 26, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced today that it is effecting a 1 for 14 reverse stock split of its common stock which will …
Corporation
Celsion Co. (NASDAQ:CLSN)‘s stock had its “hold” rating reaffirmed by equities research analysts at Maxim Group in a note issued to investors on Thursday, April 20th. The analysts wrote, “Celsion announced that the company will present …
BNS6d
Maxim
As a result of the Reverse Stock Split, every fourteen (14) shares of Common Stock outstanding immediately prior to the effectiveness of the Reverse Stock Split have been combined and converted into one share of New Common Stock
NASDAQ
If we look back year-to-date, the stock has performed -20.02%. Shares of the company have shown an EPS growth of -35.80% in the last 5 years. Its sales stood at 24.50% a year on average in the period of last five years. Celsion Co. …
Insiders
Celsion Co. (NASDAQ:CLSN)‘s stock had its “buy” rating restated by Rodman & Renshaw in a note issued to investors on Monday. They presently have a $1.50 target price on the biotechnology company’s stock. Rodman & Renshaw’s price …
Breeze1mon
Celsion (NASDAQ:CLSN) shareholders must be salivating as they wait for what they hope to be a similar move in CLSN stock when it releases its Phase III data expected in January 2013. As I detailed in my first article on CLSN, the Phase …
NASDAQ
Submitted by Michelle Price as part of our contributors program. Biotechnology stocks have done almost as well as the S&P 500 this year. They’re up 13.94% YTD, while the S&P 500 is up 14% YTD. Although this industry isn’t …
The company has a market cap of $55.64 million and a P/E ratio of 0. Get the latest Celsion (NYSE:CLSN) Stock
Celsion Co. (NASDAQ:CLSN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm currently has a $0.25 price objective on the biotechnology company’s stock. Zacks …